Navigation Links
Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
Date:4/2/2012

  Over the past few years, he has also been working to strengthen the organization and put in place the building blocks, talent and strategic collaborations to marshal the full set of global opportunities for the Company.  His years of developing and successfully launching several of the biggest medicines in the industry while in senior roles at Merck, Astra, Novartis and Vertex helped coalesce nearly a decade of innovation at Intarcia into a forward-looking and highly differentiated global Phase 3 program for ITCA 650, the Company's transformational once-yearly investigational treatment for type 2 diabetes.  

To successfully execute the global program designed to evaluate and demonstrate the superiority of ITCA 650 versus current standards of care, Mr. Graves and the team recently closed a groundbreaking deal with Quintiles, through which Quintiles is also making strategic investments in the Company and the product candidate itself.  The Company is also in the final stages of forming a second major deal around ITCA 650 with a leading global pharmaceutical company.  The collaboration is intended to create a powerful three-way global alliance to maximize the commercial potential of ITCA 650 in one of the largest and fastest growing therapeutic markets in the world.  A new Chief Medical Officer (CMO) with deep pharmaceutical and diabetes drug development experience, Michelle Baron, MD, FACE, was just recruited into the Company as well.

Mr. Graves commented on his appointment by thanking the Board and the Company's talented team of professionals who have helped drive the Company's success to date: "Intarcia has always been and continues to be an evolving story of innovation with immense potential.  It is exciting and an honor for me to be part of what turns this Company's great promise into game-changing medicines for patients and tremendous value creation
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
6. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its Series B financing, which includes both ... that would represent approximately $2.8M in new investments ... investors supported the raise. Funding ...
(Date:5/22/2013)... 2013 Genedata, a leading provider ... discovery, and life science research, today announced AB ... as its bioinformatics platform for strain genome data ... provide AB Enzymes, one of the world’s oldest ... of Genedata Selector accompanied by bioinformatics consulting services. ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... The ability to sequence genomes has ... encode. There are now a suite of applications ... protected fragments) that dramatically expand our ability to ... Dr. Jonathan Weissman, an Investigator with the University ... Institute, who will present recent applications of their ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... 3 Varian, Inc.,(NasdaqGS: VARI) announced today ... detectors (ELSD) for conventional and high speed ... and solvent,compatibility, and excellent baseline stability, Varian ... RI detectors for busy pharmaceutical,and analytical laboratories. ...
... Amarin Corporation plc,(NASDAQ: AMRN ) today ... license with,Scarista Limited ("Scarista") for the development ... portfolio in the field of lipid,science. This ... lipid-based development programs including AMR101 and its ...
... Spiral lead offers flexibility for placement in small, medium and ... ... March 3 Boston Scientific,Corporation (NYSE: BSX ) today announced ... with cardiac resynchronization therapy,defibrillators and cardiac resynchronization therapy pacemakers, both of,which ...
Cached Biology Technology:New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 4Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3
(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3MU researchers develop radioactive nanoparticles that target cancer cells 2
... Rochelle, NY, May 20, 2009Small synthetic fragments of genetic ... of abnormal proteins; however, these exciting new drug candidates ... side effects. Understanding how siRNA stimulates this undesirable immune ... design siRNA drugs to avoid it are critical topics ...
... “New Strategies for Optimizing CHO Performance,” to feature ... ZAP-CHO during BIO 2009 International Convention in Atlanta, ... / b3c newswire / – InVitria’s Director ... the performance enhancing features of ZAP-CHO, a new ...
... Barron and his group, working with labs in Italy, Germany ... means by which the deadly virus spreads by taking away ... computer simulations, researchers tested more than 100 carbon fullerene, or ... see if they could be used to inhibit a strain ...
Cached Biology News:Strong immune response to new siRNA drugs in development may cause toxic side effects 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2International team tracks clues to HIV 2International team tracks clues to HIV 3
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: